Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- MHLW Prods Univ. of Tokyo to Set Up Third-Party Panel over J-ADNI
September 1, 2014
- MHLW Notifies Prefectures of RMP Submissions for Generics
August 29, 2014
- New Chuikyo Rep Abe Credits Key Premium for Accelerating Drug Development
August 29, 2014
- MHLW Notifies Health Professionals of Revised Package Insert for Simeprevir
August 28, 2014
- Chuikyo Grants Unprecedented 60% Premium to Ono’s Opdivo
August 28, 2014
- MHLW Calls for Maintenance of Current R&D Tax Credit Limit
August 27, 2014
- PFSB’s FY2015 Budget Request Seeks Funding to Increase PMDA Staff by 13 to Strengthen Its Consultation System
August 27, 2014
- MHLW’s FY2015 Budget Request at Record 31.67 Trillion Yen, Includes 74.8 Billion Yen to Promote Commercialization of Innovative New Drugs
August 27, 2014
- PAFSC Second Committee to Review Nobelpharma’s Anticancer Drug Streptozocin on Sept. 5
August 26, 2014
- MHLW to Promote Joint Drug Development by Pharmas, Academia
August 26, 2014
- PAFSC’s First Committee to Discuss Lixiana’s Additional Use on Sept. 4
August 26, 2014
- Editor’s Pick: Five Healthcare News Headlines for August 11 - August 22
August 25, 2014
- PMDA Reviewing Lyrica for Risk of Fulminant Hepatitis, Hepatic Dysfunction
August 25, 2014
- Eisai Sues FDA over Shortened Exclusivity Time for Belviq, Fycompa
August 22, 2014
- MHLW Plans to Build Clinical Trial/Clinical Research Network with Centralized Disease-Based Patient Registry: FY2015 Preliminary Budget Request
August 22, 2014
- Report of Changes to Package Inserts to Be Required Before Providing Revised Information to Healthcare Professionals Under New System
August 21, 2014
- Health Sciences Council to Include “Program to Promote Joint Drug Development by Govt and Private Sector” in FY2015 Budget Request
August 21, 2014
- Generic Use Promotion Best Possible Way for Reducing Social Welfare Expenses: LDP Kono
August 20, 2014
- MHLW Drug Evaluation Head Eyes Flexible Designation Criteria for New Fast-Track Review System
August 19, 2014
- Emergency Use of Favipiravir to Be Permitted if Domestic Outbreak of Ebola Occurs: Health Minister
August 19, 2014
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…